Krishnaswamy Yeleswaram, Chief Development Officer at Rapport Therapeutics, Inc. (RAPP), sold 20,230 shares at $29.99 ($607K) on 2026-03-25, disclosed to the SEC on 2026-03-26.
Scheduled sale ($607k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.99 | 10,115 | $303K | 50.0% |
| 2 | $29.99 | 10,115 | $303K | 50.0% |
| Total | $29.99 avg | 20,230 | $607K | 100% |
| Filing → |
| RAPP | SELL | 2026-04-21 | $809K | — | Filing → |
| RAPP | SELL | 2026-04-14 | $696K | — | Filing → |
| RAPP | SELL | 2026-04-09 | $13K | — | Filing → |